Literature DB >> 943962

Onchocercal dermatitis: ultrastructural studies of microfilariae and host tissues, before and after treatment with diethylcarbamazine (Hetrazan).

D W Gibson, D H Connor, H L Brown, H Fuglsang, J Anderson, B O Duke, A A Buck.   

Abstract

Specimens of skin from four Cameroon patients with severe onchocercal dermatitis, before and after treatment with diethylcarbamazine (DEC), were studied by light and electron microscopy. Microfilariae of Onchocerca volvulus have ultrastructural features resembling those of microfilariae of other genera. Between the surface layer of the cuticle and the trilaminate membrane, there is an electrolucent zone which is much wider in degenerating microfilariae than in intact microfilariae. Widening of the zone may result from DEC-induced release of component(s) of the cuticle, possibly collagen or mucopolysaccharide. Between the cuticle and dermal collagen there are granular deposits which might be immune complexes involving the collagenous component of cuticle. Others have shown that DEC does not kill microfilariae in vitro. Treatment with DEC presumably "unmasks" microfilariae in the skin so that they are recognized as foreign bodies and are destroyed by the host's defenses. Histiocytes and eosinophils are seen in close proximity to degenerating microfilariae. Enzymes from histiocytes and eosinophils might readily penetrate the cuticle altered by DEC treatment, and digest various components within the microfilariae. Alternatively, the widening of the electrolucent zone might result directly from the action of leucocytic or histiocytic enzymes, after the microfilaria has been killed by other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 943962     DOI: 10.4269/ajtmh.1976.25.74

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Fate of microfilariae of Dirofilaria immitis following use of levamisole as a microfilaricide.

Authors:  C F Simpson; R F Jackson
Journal:  Z Parasitenkd       Date:  1982

2.  Diethylcarbamazine citrate, an antifilarial drug, stimulates human granulocyte adherence.

Authors:  C H King; B M Greene; P J Spagnuolo
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

3.  Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.

Authors:  A C Bird; H el-Sheikh; J Anderson; H Fuglsang
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

4.  Unique recognition of a low molecular weight Onchocerca volvulus antigen by IgG3 antibodies in chronic hyper-reactive oncho-dermatitis (Sowda).

Authors:  Z Cabrera; D W Buttner; R M Parkhouse
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

5.  Comparative analysis of a chemotherapy effect on the cuticular surface of Wuchereria bancrofti adult worms in vivo.

Authors:  A Oliveira-Menezes; R Lins; J Norões; G Dreyer; R M Lanfredi
Journal:  Parasitol Res       Date:  2007-07-12       Impact factor: 2.289

6.  Dangerous reactions to treatment of onchocerciasis with diethylcarbamazine.

Authors:  A D Bryceson; D A Warrell; H M Pope
Journal:  Br Med J       Date:  1977-03-19

7.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

8.  Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.

Authors:  Samuel Wanji; Ebanga-Echi J Eyong; Nicholas Tendongfor; Che J Ngwa; Elive N Esuka; Arnaud J Kengne-Ouafo; Fabrice R Datchoua-Poutcheu; Peter Enyong; Dalen Agnew; Rob R Eversole; Adrian Hopkins; Charles D Mackenzie
Journal:  PLoS Negl Trop Dis       Date:  2017-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.